Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 10, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 625,000 ordinary shares of 25 pence each.
- Purchase Price: 1,544.83 pence per share.
- Treasury Shares Held: 160,339,678 shares (post-transaction).
- Shares in Issue: 5,820,304,021 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 625,000 shares on May 10, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 625,000 shares by the price of 1,544.83 pence.
- Confirm the updated share capital structure: 5,820,304,021 shares in issue versus 160,339,678 shares held in Treasury.
- Note that this filing is a notification of a specific transaction and does not replace periodic financial reports (e.g., Form 20-F) for comprehensive performance analysis.